Human pharmacokinetics of WR-2721. 1986

L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman

The pharmacokinetic properties of WR-2721 were investigated in 13 cancer patients given a 150 mg/M2 intravenous bolus dose of the drug. An average plasma clearance value of 2.17 L/min was obtained. Very little of the drug or the two metabolites, WR-1065 and WR-33278, were excreted in urine obtained after the blood collection schedule. Plasma concentrations of WR-2721 decreased by 94% within 6 minutes of drug administration. The mean value of 6.44 L obtained for the steady-state volume of distribution indicates that the extravascular space occupied by the drug is small. These observations suggest that in human cancer patients, WR-2721 is rapidly taken up by tissues and converted to metabolites.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008624 Mercaptoethylamines Ethylamines, including CYSTEAMINE, that contain a sulfhydryl group in their structure.
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009946 Organothiophosphorus Compounds Compounds containing carbon-phosphorus bonds in which the phosphorus component is also bonded to one or more sulfur atoms. Many of these compounds function as CHOLINERGIC AGENTS and as INSECTICIDES. Compounds, Organothiophosphorus
D011837 Radiation-Protective Agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. Radiation Protectant,Radiation Protective Agent,Radiation-Protective Agent,Radiation-Protective Drug,Radioprotective Agent,Radioprotective Agents,Radioprotective Drug,Agents, Radiation-Protective,Radiation Protectants,Radiation Protective Agents,Radiation-Protective Drugs,Radiation-Protective Effect,Radiation-Protective Effects,Radioprotective Drugs,Agent, Radiation Protective,Agent, Radiation-Protective,Agent, Radioprotective,Agents, Radiation Protective,Agents, Radioprotective,Drug, Radiation-Protective,Drug, Radioprotective,Drugs, Radiation-Protective,Drugs, Radioprotective,Effect, Radiation-Protective,Effects, Radiation-Protective,Protectant, Radiation,Protectants, Radiation,Protective Agent, Radiation,Protective Agents, Radiation,Radiation Protective Drug,Radiation Protective Drugs,Radiation Protective Effect,Radiation Protective Effects
D004999 Amifostine A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. Ethiofos,Gammaphos,APAETP,Amifostine Anhydrous,Amifostine Disodium Salt,Amifostine Monohydrate,Amifostine Monohydrochloride,Amifostine Trihydrate,Aminopropyl Aminoethylthiophosphate,Aminopropylaminoethylthiophosphate,Aminopropylaminoethylthiophosphoric Acid,Ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester), trihydrate,Ethiofos Anhydrous,Ethyol,NSC-296961,S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid,WR-2721,YM-08310,NSC 296961,NSC296961,WR 2721,WR2721,YM 08310,YM08310
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions

Related Publications

L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
September 1984, International journal of radiation oncology, biology, physics,
L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
January 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
June 1985, International journal of radiation oncology, biology, physics,
L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
February 1987, The American journal of physiology,
L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
January 1988, Pharmacology & therapeutics,
L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
January 1988, Pharmacology & therapeutics,
L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
January 2000, Teratogenesis, carcinogenesis, and mutagenesis,
L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
August 1986, International journal of radiation oncology, biology, physics,
L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
June 1992, Pharmacology, biochemistry, and behavior,
L M Shaw, and A T Turrisi, and D J Glover, and H S Bonner, and A L Norfleet, and C Weiler, and M M Kligerman
January 1988, Pharmacology & therapeutics,
Copied contents to your clipboard!